文献速递关节外科

溃疡性结肠炎患者在全髋关节置换术后不良事件风险增加

Ulcerative Colitis Patients Are at Increased Risk for Adverse Events Following Total Hip Arthroplasty.
PubMed 文献 · J Arthroplasty · 2024-11-06

基于大型行政数据集,将接受全髋关节置换术的溃疡性结肠炎患者与无溃疡性结肠炎患者按年龄、性别和Elixhauser合并症指数4:1匹配(分别4874例和19482例),发现溃疡性结肠炎患者90天任何、严重和轻微不良事件风险均显著升高,但5年生存无差异;使用不同类别药物者不良事件风险随药物强度增加而升高。

要点

  • 溃疡性结肠炎患者全髋关节置换术后90天任何不良事件OR为1.59,严重不良事件OR为1.72,轻微不良事件OR为1.63(均P < 0.001)。
  • 无溃疡性结肠炎者相比,未用皮质类固醇/免疫调节剂/5-氨基水杨酸者OR为1.42,仅用皮质类固醇者OR为1.58,用5-氨基水杨酸±皮质类固醇者OR为1.72,用免疫调节剂±皮质类固醇者OR为1.74(均P < 0.001)。
  • 匹配组间5年生存无差异。

核心结论

  • 溃疡性结肠炎患者全髋关节置换术后90天不良事件风险高于无溃疡性结肠炎患者,且使用特定类别药物者风险更高。
  • 作者认为全髋关节置换术的溃疡性结肠炎患者需特殊考虑,外科医生必须仔细考虑和管理患者围手术期的用药方案。

研究设计与样本

  • 回顾性匹配队列研究,数据来自大型行政数据集。
  • 无溃疡性结肠炎与有溃疡性结肠炎的全髋关节置换术患者按年龄、性别和Elixhauser合并症指数4:1匹配,分别纳入19482例和4874例。
  • 比较匹配组间90天不良事件和5年生存,并根据药物类别进一步分析。

主要发现

  • 控制年龄、性别和Elixhauser合并症指数后,溃疡性结肠炎患者90天任何不良事件OR为1.59,严重不良事件OR为1.72,轻微不良事件OR为1.63(均P < 0.001)。
  • 匹配组间5年生存无差异。
  • 与无溃疡性结肠炎者相比,未用皮质类固醇/免疫调节剂/5-氨基水杨酸者任何不良事件OR为1.42,仅用皮质类固醇者OR为1.58,用5-氨基水杨酸±皮质类固醇者OR为1.72,用免疫调节剂±皮质类固醇者OR为1.74(均P < 0.001)。

临床怎么用

  • 作者认为全髋关节置换术的溃疡性结肠炎患者需特殊考虑,外科医生必须仔细考虑和管理患者围手术期的用药方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients who have the autoinflammatory bowel disease ulcerative colitis (UC) may become candidates for total hip arthroplasty (THA). Having UC may predispose patients to postoperative adverse events, but it remains unclear if these events are related more to the disease process itself or perhaps related to the medications used to treat the condition. METHODS: Patients undergoing THA were identified from a large administrative dataset. Those who did not have and those who had UC were matched 4:1 based on patient age, sex, and the Elixhauser Comorbidity Index. Matched THA patients who did not have UC (n = 19,482) and those who had UC (n = 4,874) were identified. The matched groups were compared regarding 90-day adverse and five-year survival. Further analyses were performed based on classes of medications. RESULTS: Controlling for patient age, sex, and Elixhauser Comorbidity Index, UC patients were at significantly higher odds of 90-day adverse events: any (odds ratio [OR]: 1.59), severe (OR: 1.72), and minor (OR: 1.63) (all P < 0.001). Despite this, no differences in 5-year survival were identified. Relative to those who did not have UC, there were increasing odds of any adverse event based on the potency of related medications: no corticosteroids/immunomodulators/5-aminosalicylic acid (5-ASA) (OR: 1.42), corticosteroids only (OR: 1.58), 5-ASA ± corticosteroids OR (1.72), and immunomodulators ± corticosteroids (OR: 1.74, all P < 0.001). CONCLUSIONS: Total hip arthroplasty patients who have UC were at higher odds for 90-day postoperative adverse events relative to those who did not have UC, and this risk was even greater for those on defined classes of medications. Total hip arthroplasty patients who have UC bear specific considerations, and surgeons must carefully consider and manage the patient's medication regimen in the perioperative period of the THA.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Oghenesume OP, Gouzoulis MJ, Ratnasamy PP, et al. Ulcerative Colitis Patients Are at Increased Risk for Adverse Events Following Total Hip Arthroplasty. J Arthroplasty. 2024. PMID: 39515400. doi:10.1016/j.arth.2024.10.134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。